TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01484717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management for smoking abstinence
Description: Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal nicotine
Description: Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: transdermal nicotine
Description: Participants receive an 8 week supply of transdermal nicotine \[21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)\].
Study: NCT01675518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral
Study: NCT01484717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Participants receive brief twice weekly telephone counseling.
Study: NCT01484717

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone counseling
Description: Participants receive brief twice weekly telephone counseling.
Study: NCT01667523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 1.5 mg capsaicin administered intraduodenally
Study: NCT01609790

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study: NCT01667523

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde
Description: 70 mg per intervention administered intraduodenally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline
Study: NCT05206669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Messages
Description: Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Messages
Description: Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Messages
Description: Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Messages
Description: Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Messages
Description: Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Messages
Description: Brief messages providing information about the effectiveness of HPV vaccines. Messages included embedded links where participants could find more information.
Study: NCT01961765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Study: NCT03297710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102
Description: Given PO
Study: NCT00346970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Niacin
Description: Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT04503109

Intervention type: DEVICE
Group type: OTHER
Intervention: Nalu Neurostimulation System
Description: The Nalu Neurostimulation System is a Spinal Cord Stimulation system
Study: NCT02141373

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glubran 2
Study: NCT03656718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days Permeation enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days Permeation enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days Permeation enhancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days Permeation enhancer
Study: NCT03396601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine HCl will be infused intravenously at a dose of 0.5 mg/kg over 40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline placebo will be infused IV over 40 minutes
Study: NCT02783300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3326595
Description: GSK3326595 will be administered with and without food, in tablet and capsule formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3326595
Description: GSK3326595 will be administered with and without food, in tablet and capsule formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3326595
Description: GSK3326595 will be administered with and without food, in tablet and capsule formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered.
Study: NCT06288490

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amorphous calcium carbonate
Study: NCT05632055

Intervention type: OTHER
Intervention: blood draw
Description: Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management

Intervention type: OTHER
Intervention: blood draw
Description: Blood test for miRNA and FGF21. However, the laboratory result is not reported and not involved in management
Study: NCT04082416

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard therapy
Description: Standard therapy comprises any of the following (alone or in combination):~corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
Study: NCT01609790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Administration
Description: Given IV
Study: NCT04082416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC18 160 mg plus standard therapy
Description: Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )
Study: NCT02198157

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urinary catheterization
Description: nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: urinary catheterization
Description: nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
Study: NCT02798302

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.
Description: A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.
Description: A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.
Description: A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
Study: NCT00798902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
Description: 150 micrograms/cc BVF

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest autograft
Description: autograft
Study: NCT01510340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIH-TAVIE
Description: The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
Study: NCT01609790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV
Study: NCT00764881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)
Description: Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon
Description: Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
Study: NCT01254695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic InterStim / InterStim II
Description: Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic InterStim / InterStim II
Description: Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic InterStim / InterStim II
Description: Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic InterStim / InterStim II
Description: Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic InterStim / InterStim II
Description: Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
Study: NCT03824015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keeping Adults Physically Active (KAPA) intervention
Description: The Keeping Adults Physically Active (KAPA) intervention included six 60-90 minute group motivational interviewing sessions which were supported by a pedometer and a file containing information about locally run physical activity services, a home exercise booklet and written information on different types of lifestyle and transport related physical activity. During sessions the KAPA participants created physical activity plans and reflected on their physical activity diaries and personal physical activity goals. Various sub-sets of behaviour change techniques were delivered to help support the participants in continuing to be active.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual care was delivered for the duration of the KAPA feasibility study. The usual care participants finished the original Falls Management Exercise program and went on to being offered the service provider's usual care package. Upon initiating the KAPA feasibility study it was unknown what the service provider would deliver as usual care. Therefore a study objective was to describe the usual care package delivered by the service providers.
Study: NCT00775827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate 160 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate 160 mg tablets
Study: NCT02319642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
Study: NCT01675518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT03348280

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Blood will be drawn to isolate monocytes after 2 weeks off of blood pressure lowering medications.
Study: NCT02158871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beyond Silence
Description: Pilot data from initial phases of the project and best practice principles in contact based education and adult learning theory informed curriculum design. The six in-person sessions use workplace-based vignettes to prompt reflection and discussion, build mental health literacy, reduce stigma, and promote communication and coping skill development. The virtual sessions use a secure online discussion board for participants to explore relevant online resources. All sessions will be co-led by trained peer educators; employees who have personally experienced mental ill health and recovery and are viewed as credible leaders within the organization. They will be recruited and trained to effectively teach the content, share personal experiences, and facilitate discussion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mental Health First Aid (MHFA)
Description: MHFA is a standardized, twelve-hour educational program designed to teach participants how to recognize the early warning signs of mental illness, how to provide initial help to someone in a mental health crisis, and how to support people who are developing mental health problems. It is an evidence-based approach that originated in Australia, but is being implemented across Canada, under the leadership of the Mental Health Commission of Canada. Leadership of the MHFA will be provided by an employee in each organization who has been trained through the 5-day national MHFA instructor training program. The instructor does not share any personal experiences regarding mental health issues.
Study: NCT03718026

Intervention type: OTHER
Intervention: The timed 360° turn test
Description: * The timed 360° turn test: Each participant turns around in place in a standing position for both sides.~* Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~* Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~* Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~* One-leg stance test: Individuals were asked to stand on either their left or right leg.~* Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways.

Intervention type: OTHER
Intervention: The timed 360° turn test
Description: * The timed 360° turn test: Each participant turns around in place in a standing position for both sides.~* Berg Balance Scale: It has 14 items, each of which is scored from 0 (i.e, severely impaired balance) to 4 (i.e., no balance impairment).~* Timed Up and Go test: It requires individual to stand up from an armed chair, walk 3m, turn around, walk back to the armed chair, and sit down again.~* Functional Reach Test: It measures the maximum distance an individual is able to reach forward beyond arm's length in the standing position when maintaining a fixed base of support.~* One-leg stance test: Individuals were asked to stand on either their left or right leg.~* Four square step test: It requires an individual to step over obstacles in various directions including forward, backward, and sideways.
Study: NCT02021643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT02616107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Managing Cancer Care: A Caregiver's Guide
Description: MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:~1. Becoming a Cancer Caregiver \[role, changes, challenges, adjusting, self-care\]~2. Basics of Cancer Caregiving \[physical, functional, emotional, social, \& spiritual support; treatment timeline worksheet\]~3. Caregiver's Role in Managing Patient Care \[who/what is involved; health care professionals worksheet\]~4. Managing Cancer Symptoms and Side Effects \[common symptoms/side effects; maintaining health; nutrition \& exercise; medication management worksheet\]~5. Care Options: \[information on curative, palliative and hospice care\]~6. Talking About Goals of Care \[information on goals of care conversations\]~7. Managing Transitions \[defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Management Toolkit
Description: Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
Study: NCT04588740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: concentrated beet root juice
Description: On average, we will expect subjects to ingest the supplement for approximately 5 days minimum depending on their testing schedule. On each testing day subjects will be asked to consume the two bottles of either beetroot juice (BRJ) or Placebo 2.5 hours before testing time. Specifically, for female subjects, they will be asked to start their supplementation on day 1 of menses. On day 3-4 they will take the last 2 shots. Female subjects' wash-out period will go according to their menstrual cycle as we will be controlling for hormone fluctuation (low vs high estrogen phase) know to interact with nitric oxide physiology.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo beet root juice
Description: This will follow the same supplementation regime as explained above but this supplement taste and looks exactly the same as the nitrate-rich beet root juice. It is provided by the same company that produces the concentrated beet root juice shots (Beet It, UK)
Study: NCT02021643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG
Description: Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
Study: NCT00109824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproic acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02949726

Intervention type: DRUG
Group type: OTHER
Intervention: Indocyanine Green (ICG)
Description: Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function.

Intervention type: DEVICE
Group type: OTHER
Intervention: Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)
Description: Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function.